Last reviewed · How we verify
Symbiotic
Symbiotic is a Biologic drug developed by Mashhad University of Medical Sciences. It is currently in Phase 3 development. Also known as: Probiotic ATP.
Symbiotic refers to a close and long-term biological interaction between two organisms of different species, where they benefit each other in some way. In the context of human health, symbiotic relationships can be achieved through nutritional interventions involving probiotics and prebiotics, as studied in clinical trials for conditions such as obesity and metabolic syndrome.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Symbiotic |
|---|---|
| Also known as | Probiotic ATP |
| Sponsor | Mashhad University of Medical Sciences |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC (PHASE2)
- VE303 for Prevention of Recurrent Clostridioides Difficile Infection (PHASE3)
- Multimodal Intervention for Early Chronic Kidney Disease in Young People: Dysbiosis and Inflammation (CKD) (NA)
- Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer (PHASE2)
- Human Milk Oligosaccharide-Based Synbiotic Supplement for Intestinal Microbiota Dysbiosis (EARLY_PHASE1)
- Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2) (PHASE1)
- Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers (PHASE2)
- Gut Microbiota Modulation With Synbiotics After Acute Coronary Syndrome (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Symbiotic CI brief — competitive landscape report
- Symbiotic updates RSS · CI watch RSS
- Mashhad University of Medical Sciences portfolio CI
Frequently asked questions about Symbiotic
What is Symbiotic?
Who makes Symbiotic?
Is Symbiotic also known as anything else?
What development phase is Symbiotic in?
Related
- Manufacturer: Mashhad University of Medical Sciences — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Probiotic ATP
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing